ZINBRYTA recall in Canada: risk of encephalitis
In plain language
This recall involves ZINBRYTA (daclizumab beta) sold in Canada. It's being recalled because of a risk of serious inflammatory brain disorders, including encephalitis. Stop using the product and follow the return/repair steps in the official notice.
What to do
- Stop using the product immediately.
- Contact your healthcare professional to discuss alternative treatment options.
- Report any new symptoms such as prolonged fever, severe headache, tiredness, jaundice, nausea, or vomiting to your healthcare professional.
- Undergo regular blood tests for 6 months after stopping treatment.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
ZINBRYTA (daclizumab beta)
Why this matters
Risk of encephalitis
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Risk of encephalitis
What should consumers do?
Stop using the product immediately. Contact your healthcare professional to discuss alternative treatment options. Report any new symptoms such as prolonged fever, severe headache, tiredness, jaundice, nausea, or vomiting to your healthcare professional. Undergo regular blood tests for 6 months after stopping treatment.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Risk of encephalitis
When was this product recalled?
This product was recalled on March 16, 2018.
Is the ZINBRYTA brand affected by this recall?
Yes, ZINBRYTA products are affected by this recall. This recall involves ZINBRYTA (daclizumab beta) sold in Canada. It's being recalled because of a risk of serious inflammatory brain disorders, including encephalitis. Stop using the product and follow the return/repair steps in the official notice.